Pharmaceuticals
South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $7 Mn in 2022, and is predicted to grow at (CAGR) of 7.03% from 2023 to 2030, to US $12 Mn by 2030. The key drivers of this industry include the several government initiatives and policies to support rare diseases and increased awareness among the population regarding the condition. The industry is primarily dominated by players such as Otsuka Pharmaceutical, AceLink Therapeutics, Palladio Biosciences, Reata Pharmaceutica, Xortx, Regulus Therapeutics, and Galapagos NV among others
Buy Now
South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at around US $7 Mn in 2022 and is projected to reach US $12 Mn in 2030, exhibiting a CAGR of 7.03% during the forecast period.
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition affecting multiple systems, caused by mutations in the PKD1 and PKD2 genes. It leads to the development of numerous cysts in the kidneys, causes renomegaly, and often progresses to end-stage kidney disease (ESKD). Presently, there is no cure for ADPKD, but several therapeutic options exist to manage symptoms and slow disease progression. Tolvaptan (Jinarc), created by Otsuka Pharmaceutical Co. Ltd., is an approved drug in many countries and belongs to the vasopressin V2 receptor antagonists (V2RAs) class. Tolvaptan has demonstrated the ability to decelerate cyst formation and the decline in kidney function in certain ADPKD patients. Alongside Tolvaptan, other treatment approaches include pain management and lifestyle adjustments.
The prevalence of ADPKD in South Africa is presumably low as compared to other countries, and the approximate prevalence estimate remains between 1 in 1000 individuals. The reasons for low prevalence include a limited ethnic population and genetic admixtures between them, which dilute the mutation. The market is therefore driven by major factors like government initiatives towards making ADPKD a priority condition and increased awareness about the condition in the population. However, conditions such as the non-availability of diagnostic modalities that lead to underdiagnosis in several cases, financial barriers to accessing expensive treatment, and other factors hinder the growth and potential of the market.
Market Dynamics
Market Growth Drivers
Government initiatives: The South African government decided to prioritize disorders such as ADPKD. It is working on many policies to assist rare diseases, reimbursement schemes, and taxation for companies looking to enter the market, thereby promoting market expansion.
Increased awareness: The South African market for ADPKD treatments is expanding as a result of proactive government measures such as the South African Nephrology Society and worldwide market changes. They advocate for higher research funding, better access to healthcare, and public education. This promotes market growth by encouraging early detection, adequate treatment options, and comprehensive management of disease.
Market Restraints
Limited knowledge on prevalence: The prevalence of ADPKD is considered to be presumably low as compared to all countries due to the limited availability of data about the condition. There are no clear statistics available to estimate the overall prevalence, which can therefore delay the growth of the therapeutics market.
Underdiagnosis: In South Africa, professional and general public awareness of the condition is low, resulting in delayed diagnosis and treatment of suspected patients. Diagnostic services, such as ultrasonography and genetic testing for confirmed diagnosis, are limited in public sector facilities. This leads to missed opportunities for case detection and slows market expansion.
Financial barriers: Tolvaptan, the current treatment for ADPKD, is expensive, putting a significant financial strain on both South African patients and the healthcare system. A significant portion of population lives in poverty and lacks access to costly therapies due to a lack of safe insurance options. Affordability issues lead to treatment non-adherence in many patients, slowing market growth.
Healthcare Policies and Regulatory Landscape
South Africa's healthcare policies and regulations fall under the purview of the Department of Health (DoH) and are predominantly guided by laws such as the Medicines and Related Substances Act and the Pharmacy Act. The South African Health Products Regulatory Authority (SAHPRA) is responsible for overseeing the regulation of medicines, medical devices, and diagnostics within the country.
Obtaining a license for healthcare products in South Africa requires strict adherence to SAHPRA's regulations. Companies aiming to register pharmaceuticals and medical devices must secure authorization for marketing and registration from SAHPRA, a process that involves submitting scientific and technical data to validate the product's safety, quality, and effectiveness. Additionally, companies must appoint a local importer or distributor for product liability, with certain low-risk products possibly exempt from the registration requirement.
Both the public and private healthcare sectors in South Africa present diverse opportunities for businesses operating in the healthcare industry.
Competitive Landscape
Key Players
- Otsuka Pharmaceutical Co., Ltd
- Regulus Therapeutics
- Palladio Biosciences
- Reata Pharmaceuticals
- Galapagos NV
- Exelixis Inc
- AceLink Therapeutics, Inc
- Sanofi
- Xortx Therapeutics
- Pano Therapeutics
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation
By Treatment
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By Route of Administration
- Oral
- Parenteral
- Others
By End User
- Hospitals
- Speciality Clinics
- Surgical Centres
- Others
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Pharmaceuticals
France HIV Therapeutics Market Analysis
Pharmaceuticals
Canada Blood Group Typing Market Analysis
Related reports (by geography)
Pharmaceuticals
South Africa Oncology Therapeutics Market Analysis
Pharmaceuticals
South Africa Peptic Ulcer Drugs Market Analysis
Medical Devices
South Africa Pain Management Devices Market Analysis
Pharmaceuticals
